# PK, PD, Safety and Tolerability of Lipegfilgrastim in Healthy Japanese and Caucasian Participants

> **NCT02306915** · PHASE1 · COMPLETED · sponsor: **Merckle GmbH** · enrollment: 48 (actual)

## Conditions studied

- Pharmacokinetics
- Pharmacodynamics

## Interventions

- **DRUG:** lipegfilgrastim

## Key facts

- **NCT ID:** NCT02306915
- **Lead sponsor:** Merckle GmbH
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2014-10
- **Primary completion:** 2015-03
- **Final completion:** 2015-05
- **Target enrollment:** 48 (ACTUAL)
- **Last updated:** 2021-11-09


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02306915

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02306915, "PK, PD, Safety and Tolerability of Lipegfilgrastim in Healthy Japanese and Caucasian Participants". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT02306915. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*